Robyn Karnauskas analyst TRUIST

Currently out of the existing stock ratings of Robyn Karnauskas, 261 are a BUY (84.74%), 45 are a HOLD (14.61%), 2 are a SELL (0.65%).

Robyn Karnauskas

Work Performance Price Targets & Ratings Chart

Analyst Robyn Karnauskas works at TRUIST with a stock forecast success ratio of 46.81% fulfilled within 217.88 days on average. Previously, Robyn Karnauskas worked at CITI, DEUTSCHE BANK.

Robyn Karnauskas’s has documented 619 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on GILD, Gilead Sciences at 22-Feb-2024.

Wall Street Analyst Robyn Karnauskas

Analyst best performing recommendations are on DRNA (DICERNA PHARMACEUTICALS).
The best stock recommendation documented was for DRNA (DICERNA PHARMACEUTICALS) at 11/18/2019. The price target of $24 was fulfilled within 1 day with a profit of $2.61 (12.2%) receiving and performance score of 122.02.

Average potential price target upside

ABBV AbbVie ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical BTAI BioXcel Therapeutics DCPH Deciphera Pharmaceuticals LLC GILD Gilead Sciences IMVT Immunovant  KOD Kodiak Sciences PTCT PTC Therapeutics RCUS Arcus Biosciences REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals APLT Applied Therapeutics BMY Bristol-Myers Squibb Company DRNA Dicerna Pharmaceuticals FATE Fate Therapeutics INFI Infinity Pharmaceuticals MRK Merck mpany PFE Pfizer ASMB Assembly Biosciences NCNA NuCana PLC SRPT Sarepta Therapeutics CELG Celgene OPT Opthea Ltd ROIV Roivant Sciences Ltd TIL Instil Bio . MEIP MEI Pharma MNTA Momenta Pharmaceuticals LLY Eli Lilly and Company QURE Uniqure NV CHRS Coherus BioSciences

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

189

$12.25 (6.93%)

181

18 days ago

9/13 (69.23%)

$20.33 (12.05%)

256

Buy

185

$8.25 (4.67%)

175

18 days ago

11/12 (91.67%)

$16.33 (9.68%)

140

Buy

195

$18.25 (10.33%)

180

18 days ago

7/10 (70%)

$26.33 (15.61%)

402

Hold

156

$-20.75 (-11.74%)

167

2 months 6 days ago

2/2 (100%)

$2.58 (1.68%)

109

Buy

173

$-3.75 (-2.12%)

122

2 months 13 days ago

1/3 (33.33%)

$21.76 (14.39%)

58

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Robyn Karnauskas is most bullish on?

Potential upside of $80.46 has been obtained for LLY (ELI LILLY AND COMPANY)

Which stock is Robyn Karnauskas is most reserved on?

Potential downside of -$2.07 has been obtained for PTCT (PTC THERAPEUTICS)

What Year was the first public recommendation made by Robyn Karnauskas?

On 2011

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?